Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4295 | 10049-21-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 21, 2000 | FDA | SALIX PHARMS |
None
None
None
None
None
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypophosphatemia | indication | 4996001 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Incomplete passage of stool | indication | 249515001 | |
| Calcium renal calculus | indication | 427649000 | |
| Osteopenia of prematurity | off-label use | 276703007 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| 4020416 | VUID |
| N0000148206 | NUI |
| 4018699 | VANDF |
| 4020416 | VANDF |
| C0724635 | UMLSCUI |
| CHEMBL1368 | ChEMBL_ID |
| 593YOG76RN | UNII |
| 516949 | PUBCHEM_CID |
| 221125 | RXNORM |
| 5132 | MMSL |
| 5470 | MMSL |
| 5481 | MMSL |
| 007398 | NDDF |
| 733770001 | SNOMEDCT_US |
| CHEBI:114249 | CHEBI |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| URELLE | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0037-6321 | TABLET | 40.80 mg | ORAL | Unapproved drug other | 12 sections |
| URIBEL | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0111 | CAPSULE | 40.80 mg | ORAL | unapproved drug other | 20 sections |
| Phosphasal | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0902 | TABLET | 40.80 mg | ORAL | unapproved drug other | 20 sections |
| Ustell | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0903 | CAPSULE | 40.80 mg | ORAL | unapproved drug other | 20 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-7391 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | NDA | 15 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-7391 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | NDA | 15 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-7391 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | NDA | 15 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-7391 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | NDA | 15 sections |
| K Phos Neutral | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0486-1125 | TABLET, COATED | 130 mg | ORAL | unapproved drug other | 19 sections |
| K Phos Neutral | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0486-1125 | TABLET, COATED | 130 mg | ORAL | unapproved drug other | 19 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0517-7305 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | ANDA | 12 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0517-7315 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | ANDA | 12 sections |
| Sodium Phosphates | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0517-7350 | INJECTION, SOLUTION | 276 mg | INTRAVENOUS | ANDA | 12 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6305 | SOLUTION | 140 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6307 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6308 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6312 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | Human Prescription Drug Label | 5 | 0942-6316 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6320 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6322 | SOLUTION | 140 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-6326 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0942-9201 | SOLUTION | 78 mg | INTRAVENOUS | NDA | 2 sections |
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0942-9202 | SOLUTION | 140 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9393 | SOLUTION | 155 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9394 | SOLUTION | 140 mg | INTRAVENOUS | NDA | 2 sections |
| CPDA-1 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9398 | SOLUTION | 140 mg | INTRAVENOUS | NDA | 2 sections |
| InterSol | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9601 | SOLUTION | 93 mg | INTRAVENOUS | NDA | 13 sections |
| InterSol | Human Prescription Drug Label | 5 | 0942-9602 | SOLUTION | 93 mg | INTRAVENOUS | NDA | 13 sections |
| Solucion InterSol | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9603 | SOLUTION | 93 mg | INTRAVENOUS | NDA | 14 sections |
| InterSol | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0942-9605 | SOLUTION | 93 mg | INTRAVENOUS | NDA | 13 sections |